CClinicalTrials.gg
RecruitingNCT07615686Updated Sep 15, 2026

tSCS in Children With Spina Bifida

An interventional study of Transcutaneous stimulator in Spina Bifida and Myelomeningocele, sponsored by Bailey Petersen. Recruiting at 1 site in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Bailey Petersen · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Study summary

A single-center, open-label, investigational pilot trial to explore potential effects of transcutaneous spinal cord stimulation on leg muscle strength and walking in children with myelomeningocele.

Read the detailed description

Transcutaneous, or non-invasive, spinal cord stimulation (tSCS) has been effective at improving motor control, especially walking, in adults with a variety of neuromuscular disorders and in children with spinal cord injury. Children with spina bifida often have similar difficulties with walking, muscle strength and bladder control throughout their lives, with few effective therapies to reliably improve walking. In this pilot, the investigators will test if tSCS can improve motor deficits and bladder control in children with spina bifida. The investigators are enrolling up to 20 subjects with myelomeningocele, ages 4-17 years old, that have some difficulty walking but can walk for even short distances with assistance, and that have bladder dysfunction with a stable bladder regimen. Over 4-6 weeks, children will have stimulation using non-invasive tSCS electrodes placed on their low back. Similar protocols have been used for tSCS in children with spinal cord injury and children with cerebral palsy. All previous tSCS studies have shown that this is a safe technology for use with pediatric populations. This pilot study will be used to refine the design of future randomized controlled trials to test tSCS over standard physical therapy care.

02

Conditions studied

  • Spina Bifida
  • Myelomeningocele

Keywords

  • spina bifida
  • myelomeningocele
03

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed myelomeningocele confirmed by a neurosurgeon or neurologist
  • Some difficulty ambulating, but able to ambulate at least a short distance (10 meters) with devices and/or assistance.
  • Between the ages of 4 and 17 years of age.
  • Documented neurogenic bladder dysfunction
  • On a stable bladder management regimen at least 4-6 weeks prior to the enrollment in the trial

Exclusion criteria

Exclusion Criteria:

  • Severe behavioral or cognitive impairments that preclude participation in the study, in the opinion of the investigator.
  • Has an active surgery planned for impairments from spina bifida (e.g. tethered cord syndrome surgery or orthopedic surgery) or has had surgery in the last 6 months.
  • Is pregnant. Pregnancy will be assessed via verbal report.
  • Open wounds at the thoracic or lumbar spine that precludes transcutaneous stimulation.
  • Implanted or attached electronic device in any location of the body (e.g. pacemakers, baclofen pumps, or implanted insulin pumps)
  • Symptomatic urinary tract infection, urinary tract infection for which they are currently receiving treatment, scheduled urological surgery, or inability to perform or receive catheterization.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Transcutaneous SCS

    All participants will be receiving transcutaneous spinal cord stimulation

    Device: Transcutaneous stimulator

Interventions

  • DeviceTranscutaneous stimulator

    an off the shelf TENS unit or Digitimer DS8R (using same parameters as TENS unit)

05

What researchers measure

Primary outcomes

  1. Muscle Strength

    change in isometric torque of quadriceps during knee extension

    Time frame: 4-6 weeks

  2. Gait Kinematics

    Change in joint angles in tSCS vs no stim conditions

    Time frame: 4-6 weeks

  3. Bladder capacity

    Change in cystometric bladder capacity with tSCS vs no stim conditions

    Time frame: 4-6 weeks

  4. Gait Kinetics

    Changes in ground reaction forces with and without stimulation

    Time frame: 4-6 weeks

  5. Bladder Pressure

    Change in voiding pressure with tSCS vs no stim conditions

    Time frame: 4-6 weeks

06

Study locations

1 of 1 sites recruiting
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
07

References and documents

Publications

  • Keller A, Singh G, Sommerfeld JH, King M, Parikh P, Ugiliweneza B, D'Amico J, Gerasimenko Y, Behrman AL. Noninvasive spinal stimulation safely enables upright posture in children with spinal cord injury. Nat Commun. 2021 Oct 6;12(1):5850. doi: 10.1038/s41467-021-26026-z. PubMed 34615867 ↗
  • Amirova L, Keller A, Singh G, King M, Parikh P, Stepp N, Ugiliweneza B, Gerasimenko Y, Behrman AL. Cumulative Transcutaneous Spinal Stimulation with Locomotor Training Safely Improves Trunk Control in Children with Spinal Cord Injury: Pilot Study. Children (Basel). 2025 Jun 21;12(7):817. doi: 10.3390/children12070817. PubMed 40723009 ↗
  • Neighbors E, Brunn L, Casamento-Moran A, Martin R. Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis. Children (Basel). 2024 Sep 12;11(9):1116. doi: 10.3390/children11091116. PubMed 39334648 ↗
  • Hastings S, Zhong H, Feinstein R, Zelczer G, Mitrovich C, Gad P, Edgerton VR. A pilot study combining noninvasive spinal neuromodulation and activity-based neurorehabilitation therapy in children with cerebral palsy. Nat Commun. 2022 Oct 5;13(1):5660. doi: 10.1038/s41467-022-33208-w. PubMed 36198701 ↗
  • Danielsson AJ, Bartonek A, Levey E, McHale K, Sponseller P, Saraste H. Associations between orthopaedic findings, ambulation and health-related quality of life in children with myelomeningocele. J Child Orthop. 2008 Feb;2(1):45-54. doi: 10.1007/s11832-007-0069-6. Epub 2007 Dec 15. PubMed 19308602 ↗
  • McCoy AR, Singerman L, Anand N, Kanallakan A. Spina Bifida. Phys Med Rehabil Clin N Am. 2025 Aug;36(3):513-530. doi: 10.1016/j.pmr.2025.03.003. Epub 2025 May 29. PubMed 40581437 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data collected during the trial may be shared with other researchers for the purpose of data analysis and collaboration.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT07615686
Lead sponsor
Bailey Petersen
Responsible party
Bailey Petersen (Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
May 29, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Mar 10, 2028 (estimated)
Completion
Mar 10, 2029 (estimated)
Last update
Sep 15, 2026

Study contacts

Sydney Bader, MS
Contact
syb17@pitt.edu
412-648-4196
Bailey Petersen, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion